Second, several groups, including ours [13,14,15,16,17], have reported that the therapeutic effect of anti-CTLA-4 antibodies requires ADCC activity that selectively depletes regulatory T cells in the tumor microenvironment. The gene discussed is CTLA4; the disease is neoplasm.